Retraction notice to "Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies" [Biomedicine & Pharmacotherapy 160 (2023) 114392] - 23/04/26
Doi : 10.1016/j.biopha.2026.119216
Mehrdad Hashemi a, b, Mohammad Arad Zandieh c, Yasmin Talebi a, Parham Rahmanian d, Sareh Sadat Shafiee a, Melina Maghsodlou Nejad d, Roghayeh Babaei a, Farzaneh Hasani Sadi e, Romina Rajabi d, Zahra Oryan Abkenar f, Shamin Rezaei a, Jun Ren g, Noushin Nabavi h, Ramin Khorrami i, Mohsen Rashidi j, k, ⁎, Kiavash Hushmandi c, ⁎, Maliheh Entezari a, b, ⁎, Afshin Taheriazam a, l, ⁎
a Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical sciences, Islamic Azad University, Tehran, Iran
b Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
c Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
d Faculty of Veterinary Medicine, Islamic Azad University, Science and Research Branch, Tehran, Iran
e General Practitioner, Kerman University of Medical Sciences, Kerman 7616913555, Iran
f Department of Biology, Islamic Azad University of Damghan, Damghan, Iran
g Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
h Department of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, V6H3Z6 Vancouver, BC, Canada
i Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
j Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
k The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran
l Department of Orthopedics, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
⁎ Corresponding authors.
Le texte complet de cet article est disponible en PDF.
© 2026
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 198
Article 119216- mai 2026 Retour au numéro
Article précédent
- Corrigendum to “Ceftriaxone administration reduces vascular calcification associated with experimental models of chronic kidney disease.” [Biomed. Pharmacother. 197 (2026), 119131]
- Teresa Obrero-Sojo, Ma José Jiménez-Moral, Fátima Guerrero, Ma Encarnación Rodríguez-Ortiz, Ana Isabel Torralbo, Karen Valdés-Díaz, Raquel Ma García-Sáez, Antonio Rivas-Domínguez, Daniel Jurado-Montoya, Fernando Leiva-Cepas, Ma Victoria Pendón-Ruiz de Mier, Cristian Rodelo-Haad, Griet Glorieux, Mariano Rodríguez, Sagrario Soriano-Cabrera, Juan Rafael Muñoz-Castañeda
- Retraction notice to "Inhibition of non-muscular myosin light chain kinase accelerates the clearance of inflammatory cells by promoting the lysosome-mediated cell death" [Biomedicine & Pharmacotherapy 170 (2024) 115986]
- Junsong Wu, Muhammad Qasim Barkat, Jiakun Su, Fugen Wu, Dan Tan, Tingyu Shen, Qiangqiang He, Meiyu Qu, Meiping Lu, Jibao Cai, Ximei Wu, Chengyun Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?